Safety Study of Three Concentrations of UniPron Vaginal Contraceptive Microbicidal Gel

Obiero Jael^{1, 2,} , Waititu Kenneth Kariuki^{3, 2} and Mwethera Peter Gichuhi¹

¹Department of Reproductive Health and Biology, Institute of Primate Research, Nairobi, Kenya

²Department of Medical Microbiology, Jomo Kenyatta University of Agriculture and Kenya Kenya Technology, Nairobi, Kenya

³Animal Sciences Department, Institute of Primate Research, Nairobi, Kenya

Cite this paper:
Obiero Jael, Waititu Kenneth Kariuki and Mwethera Peter Gichuhi. Safety Study of Three Concentrations of UniPron Vaginal Contraceptive Microbicidal Gel. American Journal of Biomedical Research. 2018; 6(2):33-39. doi: 10.12691/ajbr-6-2-1

Abstract

Background: UniPron is an antimicrobial and a spermicidal agent that contains citric acid as the active component. This study was designed to evaluate the effects of three different concentrations of UniPron in the baboon (Papio anubis) model. Methods: Twenty sexually mature female baboons were used in this study. Vaginal pH and microflora, blood chemistry, vaginal and cervical histology were evaluated at baseline and after administration of 15 ml of UniPron 0.4, 0.8 and 1.2 gm or placebo twice a week for eight weeks to each randomized treatment group. Results: Baseline vaginal pH was 5.2±0.8. There was no significant difference in the vaginal pH and blood chemistry parameters. The microflora composition was diverse and slight variation in percentage frequency between UniPron concentrations was observed. No detectable histological changes were observed in the vaginal or cervical sections. Conclusion: Repeated application of 15 ml of three UniPron concentrations appeared to be safe when administered intravaginally in the baboon model.

Keywords:
UniPron baboon safety vagina microbicide contraceptive

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Potts M. (1994). The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am J Public Health. 84: (6): 890-1.
[2]	Thurman AR, Clark MR & DoncelGF. (2011). Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies. Infect Dis Obstet Gynecol. 2011:1-10.
[3]	Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, MansoorLE,Kharsany ABM, Sibeko S,1 Mlisana KP, Omar, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L & Taylor D. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 329: (5996):1168-74.
[4]	Ashish J Lokesh K, Bhavana K, Monika S, Aastha P, Vikas V, Vikas S, Vishal S, Tara R & Vishnu L. S. (2013). Combining a synthetic spermicide with a natural trichomonacide for safe, prophylactic contraception. Hum. Reprod.
[5]	Keller MJ, Carpenter CA, Lo Y, Einstein MH, Liu C, Fredricks DN & Herold BC. (2012). Phase I Randomized Safety Study of Twice Daily Dosing of Acidform Vaginal Gel: Candidate Antimicrobial Contraceptive. PLOS One 7:10:e46901.
[6]	Elias CJ & Heise LL (1994). Challenges for the development of female-controlled vaginal microbicides. AIDS. 8: (1):1-9.
[7]	Uckun FM, D’Cruz OJ. Prophylactic contraceptives for HIV/AIDS. Human Reprod Update, 1999, 5: (5): 506-14.
[8]	D’Cruz OJ & (2004). Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Design. 10: (3): 315-36.
[9]	Obiero J, Maureen, Ndung’u, M. Waititu KK, Mulei I, Farah IO& Peter G. Mwethera UniPron is A Fully Effective Non-hormonal Reversible Contraceptive in Baboon Model (Papio Anubis). (2008). J Reprod & Contracep. 19: (2): 107-18.
[10]	Mburu N, Obiero JA, Waititu K, Mwaura BN, Orawo JO, Farah IO & Mwethera PG. (2009). Safety Studies of a Recently Developed Microbicidal Contraceptive Gel (UniPron) in Female Baboons (Papio anubis). Afri J Reprod Health. 13: (4):95-104.
[11]	McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C & Jacobson C. (2011). Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS. 25(8):1057-64.
[12]	Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S & Karim SS. (2013). Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther. 18: (3):301-10.
[13]	Grammen C\, Ariën KK, Venkatraj M, Joossens J, Van der Veken P, Heeres J, Lewi PJ, Haenen S, Augustyns K, Vanham G, Augustijns P & Brouwers J. (2014). Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antiviral Res. 101: 113-21.
[14]	Wilkinson D, Tholandi M, Ramjee G, & Rutherford GW. (2002). Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002; 2: 613-7.
[15]	Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M. (2002). Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 360: (9338): 971-7.
[16]	Obiero J, Mwethera PG &Wiysonge CS. (2012). Topical microbicides for prevention of sexually transmitted infections (2012). Cochrane Database System Rev. Issue 6. Art. No.: CD007961.
[17]	Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. (2012). Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infectious Diseases. 12: 289.
[18]	Obiero JA, Kunyera R, waititu KK, Mulei I, Farah IO, Linge K, Jaoko W & Mwethera PG. (2013). A Comparative Study of Smugel and KY Jelly Vaginal Lubricating Gels. J Reprod Contracep. 24: (2):76-87.
[19]	Nyachieo A, Kiulia NM, Arimi MM, et al. Vaginal histological changes of the baboon during the normal menstrual cycle and pregnancy. East Afr Med J, 2009, 86(4):166-72.
[20]	Sobel JD. (2000). Bacterial vaginosis. Annu Rev Med. 2000. 51:349-356.
[21]	Ursell LK, Gunawardana M, Chang S, Mullen M, Moss JA, Herold BC, Keller MJ, McDonald D, González A, Knight R & Baum MM. (2013). Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings. Antiviral Res. 19: (102C): 87-94.
[22]	Rose WA II, McGowin CL, Spagnuolo RA, Eaves-Pyles TD, Popov VL & Pyles RB. (2012). Commensal Bacteria Modulate Innate Immune Responses of Vaginal Epithelial Cell Multilayer Cultures. PLoS One. 7: (3): e32728.
[23]	Rivera, AJ, Stumpf RM, Wilson B, Leigh S & Salyers AA. (2010). Baboon vaginal microbiota: an overlooked aspect of primate physiology. Am J Primatol. 72: (6): 467-74.
[24]	Fichorova RN, Yamamoto HS, Delaney ML, Onderdonk AB & Doncel GF. (2011). Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. mBio. 2: (6):e00168-11.
[25]	Stafford MK, Ward W, Flanagan A, Rosenstein IJ Taylor-Robinson D, Smith JR, Weber J & Kitchen VS. (1998). Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol. 17: 327-31.
[26]	Richardson BA, Martin HL Jr, Stevens CE, Hillier SL, Mwatha AK, Chohan BH, Nyange PM, Mandaliya K, Ndinya-Achola J & Kreiss JK. (1998). Use of nonoxynol-9 and changes in vaginal lactobacilli. J Infect Dis. 178: (2): 441-5.
[27]	Veazey RS. (2008). Microbicide Safety/Efficacy studies in animals -macaques and small animal models. Curr Opin HIV AIDS. 3: (5).
[28]	Rosenberg ZF & Devlin B. (2012). Future strategies in microbicide development. Best Pract Res Clin Obstet Gynaecol. 26: (4): 503-13.